CSL (CSLLY) Stock Based Compensation: $0 Mil (TTM As of Dec. 2025)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $19.98
GF Value $48.70
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Stock Based Compensation?

CSL CSLLY -2.30% 73 Stock Based Compensation is $0 Mil as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $48.70 (Significantly Undervalued). The stock has 7 warning signs investors should review.

CSL's Stock Based Compensation for the six months ended in Dec. 2025 was $0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0 Mil.

CSL Stock Based Compensation Related Terms

CSL Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for CSL's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Stock Based Compensation Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CSLLY
73GF Score
CSL Ltd CSLLY
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

What does a Stock Based Compensation of $0 Mil mean?
CSL (CSLLY) has a Stock Based Compensation of $0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CSL and its competitors.
Is CSL's Stock Based Compensation too high?
CSL's current Stock Based Compensation is $0 Mil. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Stock Based Compensation compare to VRTX and REGN?
CSL's Stock Based Compensation of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CSL and its competitors. CSL's current Stock Based Compensation is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.70, compared to a current price of $19.98 — trading 59% below its estimated fair value. The current Stock Based Compensation is $0 Mil. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For CSL (CSLLY), the current Stock Based Compensation is $0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $19.98 is trading 59% below its estimated GF Value™ of $48.70. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Stock Based Compensation: $0 Mil
  • GF Value™: $48.70 vs. price of $19.98 (59% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.98
Price
$48.70
GF Value